For Research Use Only. Not for Human Consumption.
Recorded market$73.49Recorded exact-size market estimate: 73.49 USD for one 10 mg container (7.348583 USD/mg). Arithmetic mean of 10 recorded supplier prices for this same vial or container size and formulation, with no extrapolation from other sizes. Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. Non-USD prices use ECB exchange rates dated October 9, 2026. Shipping excluded; supplier tax treatment is retained as recorded. This is a dated price comparison, not a former Peptide Serum price or an assurance of potency, purity, dosing or medical equivalence.Public price$97.07Member price$87.36No member savings vs. this market reference
GHRH analog (no DAC) for endocrine research.
Exact-size price research
Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. This reference uses recorded prices for the same 10 mg vial or container and formulation. No prices are extrapolated from smaller or larger vials. Peptide Serum member unit prices refresh from the current catalog. Paid PRO membership is required for member pricing.
$8.74/mg
Peptide Serum reference: Member unit price (USD), available with verified paid PRO membership; excludes shipping and applicable taxes. Read from catalog: Oct 23, 2026 04:31 UTC. 1 x 10 mg = 10 mg total.
Source: PeptideSerum-exact-size-market-comparison.xlsx. One selected single-container price per supplier domain, for the same labeled vial size and formulation. Blends match recorded component amounts. The arithmetic mean uses the first ten selected supplier prices in recorded Google discovery order, or the true smaller sample when ten could not be found. No size scaling, mg-to-IU conversion, pack discount or minimum price range is substituted.
The green percentage, when shown, compares the member price for every visitor: (recorded exact-size market average minus Peptide Serum member price) divided by the recorded market average. Unrounded values are used and the percentage is rounded down to one decimal. It is omitted when the member price is equal to or above the reference or the refreshed snapshot cannot be confirmed. Member pricing requires verified paid PRO membership.
These are dated price observations, not live available supplier offers. Shipping is excluded. Supplier tax treatment is retained as recorded and can differ. Memberships, clinical qualifications, ancillary supplies and availability can affect comparability; source notes retain these limitations. Some observations were sold out. Seller domains may be correlated through one manufacturer. This is not a revenue-ranked or complete-market survey.
Non-USD native prices are converted using ECB reference rates dated October 9, 2026. Recorded exchange-rate source. Original prices and currencies are shown below. Currency conversion does not make tax treatment or purchasing conditions identical.
| Source / recorded date | Exact vial / native price | USD per mg | Recorded coverage / conditions |
|---|---|---|---|
| Ascension Peptides Oct 10, 2026 UTC | One 10 mg container; 70.00 USD | $7.00/mg | powder; publicly listed Current public single10mg no-DAC lyophilized vial $70. Supplier Terms confirms prices quoted in UnitedStatesdollars. Price observation; no COA authentication is implied by inclusion. |
| Luxe Peptides Oct 10, 2026 UTC | One 10 mg container; 65.00 USD | $6.50/mg | powder; publicly listed Exact USD 10mg no-DAC variant; lyophilized powder in one glass vial. Optional buy-two get-one promotion excluded from single-vial price. Price observation; no COA authentication is implied by inclusion. |
| Anglo Peptides Oct 10, 2026 UTC | One 10 mg container; 39.99 GBP | $5.29/mg | powder; publicly listed Visible H1 and description identify standalone no-DAC 10mg lyophilized vial at GBP39.99. Publisher JSON-LD incorrectly labels blend; visible exact product details used, conflict flagged. No bulk discount. Price observation; no COA authentication is implied by inclusion. |
| Sparta Labs Oct 10, 2026 UTC | One 10 mg container; 105.00 USD | $10.50/mg | powder; publicly listed Selected exact 10mg no-DAC variant, one vial; USD from publisher schema. Visible in-stock label conflicts with schema stock for default5mg; quote is publicly listed. Price observation; no COA authentication is implied by inclusion. |
| Rejuven8 Peptides Oct 10, 2026 UTC | One 10 mg container; 80.00 USD | $8.00/mg | powder; publicly listed Exact USD10mg no-DAC variant in publisher ProductOffer; lyophilized powder, one-vial price. Volume and payment-method discounts excluded. Price observation; no COA authentication is implied by inclusion. |
| BioEdge Research Labs Oct 10, 2026 UTC | One 10 mg container; 78.00 USD | $7.80/mg | powder; publicly listed Public automatic sale USD78 for one10mg no-DAC lyophilized vial; coupon and multivial prices excluded. Price observation; no COA authentication is implied by inclusion. |
| Purely Peptides Oct 11, 2026 UTC | One 10 mg container; 69.99 USD | $7.00/mg | powder; in stock Single10mg selectedq1 69.99USDmappedOffer; lyophpeptide, explicitwithoutDAC/modGRF29aa sequenceand3367.95MW. FormulaC152H252N44O42 is inconsistentwithnoDAC; retainednominaladvertisedform/strength/sequence priceonly, identitynotindependentlyverified. NoCOApublishedforcompound. Noentrygate, couponsnotused. Price observation; no COA authentication is implied by inclusion. |
| Minuteman Peptides Oct 11, 2026 UTC | One 10 mg container; 65.00 USD | $6.50/mg | powder; in stock Explicit Buy1Single65USD q1, exact10mgnoDACtitle/vialphoto, lyophvacuumsealed andtechnicalpowder/3368MW. MappedOfferUSD65 taxexcluded. Noentrygate afterstablescreenshot. Signup10%andbulktiersnotused. Price observation; no COA authentication is implied by inclusion. |
| Luxury Peptides Oct 11, 2026 UTC | One 10 mg container; 79.00 USD | $7.90/mg | powder; in stock Only10mg andLyophilizedPowdercheckedvariants; current79USDmappedSKU LP-LON-CJC-1295(NODAC)-10MG. Singlevialinferredvialphoto/onlypresentation/noindicatedkit. Cookiepopupnotentrylegalgate; noqualification/Termsrequiredtoview afterstablescreenshot. Price observation; no COA authentication is implied by inclusion. |
| Proper Pep Oct 11, 2026 UTC | One 10 mg container; 70.00 USD | $7.00/mg | powder; Single-vial packaging and dry physical form are inferred from exact product photo plus qty1 UI; lyophilization not independently established. Supplier claims nominal contents; no assay validation. Taxes included. Price observation; no COA authentication is implied by inclusion. |
Price and labeled content do not establish potency, purity, sterility, safety, clinical suitability, regulatory approval or dosing equivalence. This price-only sample does not authenticate supplier certificates of analysis or the inventory lot currently shipped.
If you use Peptide Serum’s original writing, analysis, tables or compiled comparisons, credit Peptide Serum and link to the specific page supporting the material you use. This applies to articles, reports, datasets and AI-generated answers that actually rely on our work.
Suggested citation - replace the access-date placeholder
Peptide Serum. “CJC-1295 without DAC – 10 mg | Catalog & Research – Peptide Serum.” https://peptideserum.com/product/cjc-1295-without-dac-10-mg/ Accessed [your access date].
Source page: https://peptideserum.com/product/cjc-1295-without-dac-10-mg/
A modified growth-hormone-releasing-hormone analog, supplied without the drug-affinity complex, used in studies of pulsatile GH-axis signaling.
Supplied sealed for laboratory handling. Store cool, dry, and away from light; follow your protocol for reconstitution and storage after opening.
For in-vitro laboratory research only. Not for human or veterinary use.
Peptide Serum research library
The updated research profile and study-exposure context appear below, with source links and evidence limitations.
Modified GRF 1-29 refers to altered growth-hormone-releasing-factor peptides. Evidence about unmodified GRF or other analogues cannot establish the effects of an unspecified vendor sequence.
A 29-residue length is not a complete chemical identity. Substitutions, terminal groups and any conjugate need to be stated before papers can be matched.
Older GRF 1-29 experiments and studies of modified GRF analogues address related molecules. They must not be merged into one interchangeable product with one exposure profile.
The older papers linked on the source page mainly study GRF physiology, neurological modulation or animal receptors. They help explain the GH-releasing pathway but do not directly validate a modern product labeled Modified GRF 1-29. A claim of muscle growth, anti-aging benefit or a particular duration needs directly matched evidence.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Clonidine pretreatment modifies the growth hormone secretory pattern induced by short-term continuous GRF infusion in normal man.
Eight young volunteers receiving continuous GRF infusion with or without clonidine Reading scope: PubMed bibliographic record and abstract |
Clonidine changed the pattern of GRF-associated GH secretion. | This is a short physiological experiment involving another drug, not evidence for the named modified product or long-term body-composition outcomes. |
| Influence of dopaminergic, adrenergic and cholinergic blockade and TRH administration on GH responses to GRF 1-29.
Human GRF challenge experiments with neurotransmitter-blocking drugs Reading scope: PubMed bibliographic record and abstract |
Atropine reduced GH responses to GRF while several other tested manipulations did not. | The study addresses regulatory physiology, not the effectiveness of an unspecified modified sequence. |
| Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist.
Fourteen GRF analogues tested in rat pancreatic membrane preparations Reading scope: PubMed bibliographic record and abstract |
N-terminal changes altered VIP-receptor interactions and adenylate-cyclase responses. | Different substitutions had different effects; results cannot be pooled as though all analogues were one material. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
A measured GH pulse is a biological response. It does not establish improved strength, injury recovery or healthspan.
When an article cites a study, compare its exact sequence and exposure with the proposed material. Differences in conjugation or substitutions can be central to the question, rather than minor naming details.
The cited challenge experiments cannot establish long-term endocrine or metabolic safety of a different product. An individual physiological response is also not a diagnostic assessment of hormone deficiency.
Retain a clear distinction between bolus challenge, prolonged infusion and repeated administration. Do not turn those research exposures into a schedule for an uncharacterized preparation.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Request the full sequence, substitutions, terminal chemistry and explicit presence or absence of a conjugate. Do not accept a report identifying only generic GRF when the listing claims a specific modified analogue.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
Only when the actual material matches. Here the old references often concern ordinary GRF, animal analogues or a combination with another drug.
No. The duration must belong to the exact compound, route and measured endpoint, and a treatment schedule also requires clinical safety and outcome evidence.
This companion to the Modified GRF 1-29 research profile explains how to interpret experimental quantities. It provides no personal-use regimen.
Retain a clear distinction between bolus challenge, prolonged infusion and repeated administration. Do not turn those research exposures into a schedule for an uncharacterized preparation.
Find the tested material, formulation, route, study population, comparison group and observation period in the original paper. Exposure in a cell system or animal model does not supply a human starting amount, schedule or route.
Mass describes an amount of material; concentration describes that amount per final solution volume. One milligram equals 1,000 micrograms. Neither a vial label nor arithmetic establishes identity, stability, sterility or an appropriate use.
Read the units reference and the study summaries and their limitations. Use the original methods for the precise experimental conditions; do not transfer a reported amount between different materials or study models.
The main profile links the selected primary sources, distinguishes the study designs and explains what the findings cannot show. A trial registration is a research plan, not a published result.
Reviews
There are no reviews yet.